News | 02 March 2024
Warren Remedies commences commercial production of oral care products
The production started from its greenfield manufacturing facility at Aurangabad in Maharashtra
The production started from its greenfield manufacturing facility at Aurangabad in Maharashtra
Cipla completes transfer of Generics Business Undertaking
.jpg)
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
Eugia Pharma Specialities restarts production at terminally sterilized product lines
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
BHL will undertake the development and supply of these molecules
_in_Mizushima,_Japan.jpg){kind=spacer}
Contributing to lower risk of potentially carcinogenic nitrosamine impurities in pharmaceuticals
The plant will drive pharmaceutical innovation in the Northeastern India
The facility will accommodate over 1,500 employees
Varenicline is indicated for smoking cessation in adults
The contract awarded to Kilitch Estro Biotech PLC entails the supply of pharmaceuticals with an order size amounting to US$ 9.13 million
Both the Ministries signed MoU for anaemia control among adolescent girls using Ayurveda interventions
The board gave in-principle approval for expansion of company's footprint in Lucknow
Suven Pharmaceuticals’ API and forumulations facilities complete USFDA inspection successfully
_Rupak_Singla.jpg)
Experts discussed the latest innovations, challenges, & collaborative solutions in the fight against TB at NHWIC-2024 held at AIIMS, Delhi
.jpg)
The Vice President also highlighted the importance of preventive healthcare and fitness
The acquisition enriches AstraZeneca’s growing pipeline of cell therapies with GC012F
The acquisition of Healint aligns with Aptar Digital Health’s strategy to broaden its portfolio in neurology and strengthen its global footprint for digital health deployment
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)
